Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma

Kerstin Wenzl, Michelle K. Manske, Vivekananda Sarangi, Yan Asmann, Patricia T Greipp, Hanna R. Schoon, Esteban D Braggio, Matthew J. Maurer, Andrew L Feldman, Thomas Elmer Witzig, Susan L Slager, Stephen Maxted Ansell, James R Cerhan, Anne J Novak

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

MYD88 mutations are one of the most recurrent mutations in hematologic malignancies. However, recent mouse models suggest that MYD88L265P alone may not be sufficient to induce tumor formation. Interplay between MYD88L265P and other genetic events is further supported by the fact that TNFAIP3 (A20) inactivation often accompanies MYD88L265P. However, we are still lacking information about the consequence of MYD88L265P in combination with TNFAIP3 loss in human B cell lymphoma. Review of our genetic data on diffuse large B cell lymphoma (DLBCL) and Waldenstrom macroglobulinemia (WM), found that a large percentage of DLBCL and WM cases that have a MYD88 mutation also harbor a TNFAIP3 loss, 55% DLBCL and 28% of WM, respectively. To mimic this combination of genetic events, we used genomic editing technology to knock out TNFAIP3 in MYD88L265P non-Hodgkin’s lymphoma (NHL) cell lines. Loss of A20 expression resulted in increased NF-κB and p38 activity leading to upregulation of the NF-κB target genes BCL2 and MYC. Furthermore, we detected the increased production of IL-6 and CXCL10 which led to an upregulation of the JAK/STAT pathway. Overall, these results suggest that MYD88L265P signaling can be enhanced by a second genetic alteration in TNFAIP3 and highlights a potential opportunity for therapeutic targeting.

Original languageEnglish (US)
Article number97
JournalBlood Cancer Journal
Volume8
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Waldenstrom Macroglobulinemia
Lymphoma, Large B-Cell, Diffuse
Non-Hodgkin's Lymphoma
Mutation
Up-Regulation
B-Cell Lymphoma
Hematologic Neoplasms
Interleukin-6
Technology
Cell Line
Genes
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. / Wenzl, Kerstin; Manske, Michelle K.; Sarangi, Vivekananda; Asmann, Yan; Greipp, Patricia T; Schoon, Hanna R.; Braggio, Esteban D; Maurer, Matthew J.; Feldman, Andrew L; Witzig, Thomas Elmer; Slager, Susan L; Ansell, Stephen Maxted; Cerhan, James R; Novak, Anne J.

In: Blood Cancer Journal, Vol. 8, No. 10, 97, 01.10.2018.

Research output: Contribution to journalArticle

@article{e6afe49b23584c2cadcfde97de995371,
title = "Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma",
abstract = "MYD88 mutations are one of the most recurrent mutations in hematologic malignancies. However, recent mouse models suggest that MYD88L265P alone may not be sufficient to induce tumor formation. Interplay between MYD88L265P and other genetic events is further supported by the fact that TNFAIP3 (A20) inactivation often accompanies MYD88L265P. However, we are still lacking information about the consequence of MYD88L265P in combination with TNFAIP3 loss in human B cell lymphoma. Review of our genetic data on diffuse large B cell lymphoma (DLBCL) and Waldenstrom macroglobulinemia (WM), found that a large percentage of DLBCL and WM cases that have a MYD88 mutation also harbor a TNFAIP3 loss, 55{\%} DLBCL and 28{\%} of WM, respectively. To mimic this combination of genetic events, we used genomic editing technology to knock out TNFAIP3 in MYD88L265P non-Hodgkin’s lymphoma (NHL) cell lines. Loss of A20 expression resulted in increased NF-κB and p38 activity leading to upregulation of the NF-κB target genes BCL2 and MYC. Furthermore, we detected the increased production of IL-6 and CXCL10 which led to an upregulation of the JAK/STAT pathway. Overall, these results suggest that MYD88L265P signaling can be enhanced by a second genetic alteration in TNFAIP3 and highlights a potential opportunity for therapeutic targeting.",
author = "Kerstin Wenzl and Manske, {Michelle K.} and Vivekananda Sarangi and Yan Asmann and Greipp, {Patricia T} and Schoon, {Hanna R.} and Braggio, {Esteban D} and Maurer, {Matthew J.} and Feldman, {Andrew L} and Witzig, {Thomas Elmer} and Slager, {Susan L} and Ansell, {Stephen Maxted} and Cerhan, {James R} and Novak, {Anne J}",
year = "2018",
month = "10",
day = "1",
doi = "10.1038/s41408-018-0130-3",
language = "English (US)",
volume = "8",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma

AU - Wenzl, Kerstin

AU - Manske, Michelle K.

AU - Sarangi, Vivekananda

AU - Asmann, Yan

AU - Greipp, Patricia T

AU - Schoon, Hanna R.

AU - Braggio, Esteban D

AU - Maurer, Matthew J.

AU - Feldman, Andrew L

AU - Witzig, Thomas Elmer

AU - Slager, Susan L

AU - Ansell, Stephen Maxted

AU - Cerhan, James R

AU - Novak, Anne J

PY - 2018/10/1

Y1 - 2018/10/1

N2 - MYD88 mutations are one of the most recurrent mutations in hematologic malignancies. However, recent mouse models suggest that MYD88L265P alone may not be sufficient to induce tumor formation. Interplay between MYD88L265P and other genetic events is further supported by the fact that TNFAIP3 (A20) inactivation often accompanies MYD88L265P. However, we are still lacking information about the consequence of MYD88L265P in combination with TNFAIP3 loss in human B cell lymphoma. Review of our genetic data on diffuse large B cell lymphoma (DLBCL) and Waldenstrom macroglobulinemia (WM), found that a large percentage of DLBCL and WM cases that have a MYD88 mutation also harbor a TNFAIP3 loss, 55% DLBCL and 28% of WM, respectively. To mimic this combination of genetic events, we used genomic editing technology to knock out TNFAIP3 in MYD88L265P non-Hodgkin’s lymphoma (NHL) cell lines. Loss of A20 expression resulted in increased NF-κB and p38 activity leading to upregulation of the NF-κB target genes BCL2 and MYC. Furthermore, we detected the increased production of IL-6 and CXCL10 which led to an upregulation of the JAK/STAT pathway. Overall, these results suggest that MYD88L265P signaling can be enhanced by a second genetic alteration in TNFAIP3 and highlights a potential opportunity for therapeutic targeting.

AB - MYD88 mutations are one of the most recurrent mutations in hematologic malignancies. However, recent mouse models suggest that MYD88L265P alone may not be sufficient to induce tumor formation. Interplay between MYD88L265P and other genetic events is further supported by the fact that TNFAIP3 (A20) inactivation often accompanies MYD88L265P. However, we are still lacking information about the consequence of MYD88L265P in combination with TNFAIP3 loss in human B cell lymphoma. Review of our genetic data on diffuse large B cell lymphoma (DLBCL) and Waldenstrom macroglobulinemia (WM), found that a large percentage of DLBCL and WM cases that have a MYD88 mutation also harbor a TNFAIP3 loss, 55% DLBCL and 28% of WM, respectively. To mimic this combination of genetic events, we used genomic editing technology to knock out TNFAIP3 in MYD88L265P non-Hodgkin’s lymphoma (NHL) cell lines. Loss of A20 expression resulted in increased NF-κB and p38 activity leading to upregulation of the NF-κB target genes BCL2 and MYC. Furthermore, we detected the increased production of IL-6 and CXCL10 which led to an upregulation of the JAK/STAT pathway. Overall, these results suggest that MYD88L265P signaling can be enhanced by a second genetic alteration in TNFAIP3 and highlights a potential opportunity for therapeutic targeting.

UR - http://www.scopus.com/inward/record.url?scp=85054586721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054586721&partnerID=8YFLogxK

U2 - 10.1038/s41408-018-0130-3

DO - 10.1038/s41408-018-0130-3

M3 - Article

VL - 8

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 10

M1 - 97

ER -